1. Bridging therapy in antiphospholipid syndrome and antiphospholipid antibodies carriers: case series and review of the literature.
- Author
-
Raso S, Sciascia S, Kuzenko A, Castagno I, Marozio L, and Bertero MT
- Subjects
- Antibodies, Antiphospholipid analysis, Antiphospholipid Syndrome immunology, Hemorrhage prevention & control, Humans, Risk Factors, Thromboembolism prevention & control, Anticoagulants administration & dosage, Antiphospholipid Syndrome drug therapy, Heparin administration & dosage, Perioperative Period, Warfarin administration & dosage
- Abstract
Peri-operative management of patients on warfarin involves assessing and balancing individual risks for thromboembolism and bleeding. The timing of warfarin withdrawal and a tailored pre/postoperative management (including the substitution of heparin in place of warfarin, the so-called bridging therapy) is critical in patients with prothrombotic conditions. The antiphospholipid syndrome (APS) is the most common cause of acquired thrombophilia. In this particular subset of patients, as the risk of thrombosis is higher than in general population, bridging therapy can represent a real challenge for treating physicians. Only few studies have been designed to address this topic. We aim to report our experience and to review the available literature in the peri-procedural management of APS and antiphospholipid antibody-positive patients, reporting adverse events and attempting to identify potential risk factor associated with thrombosis or bleeding complications., (Copyright © 2014 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF